Page 76 - 2019秋季手冊內頁-ebook測試
P. 76
definitive concurrent chemoradiotherapy. American Journal of Nuclear Medicine and Molecular Imaging. 6 (3), 166
CONFERENCE PAPERS:
• Ho TY, Yen TC. Thyroid incidentalmoa detected by FDG PET, Society of Nuclear Medicine
Meeting, Salt Lake City, Utah, June 2010 (Oral Presentation)
• Ho TY, Lin J, Yen TC. Significance of FDG PET/CT in Clinically Suspicious Supraclavicular Lymph
Nodes in Primary Lung Cancer Pateints, EANM, Milan, Italy, Oct 2012 (Poster)
• Chao KT, Ho TY. Quantitative correlation of lymphedema by lymphoscintigraphy,
International Symposium on Surgical Treatments of Lymphedema, Taoyuan, Taiwan,
Apr 2013 (Oral Presentation)
• Ho TY, Chen SC, Yen TC. Experience of Ga-68 DOTATOC in neuroendocrine tumors in Taiwan,
International Conference of Pancreatic Malignancy, Taoyuan, Taiwan, Nov 2014 (Oral
Presentation)
• Ho TY, Yen TC. TLG Determined per RECIST 1.1 Criteria Predicts Survival in EGFR Mutation-
Negative Patients with Advanced Lung Adenocarcinoma, Society of Nuclear Medicine Annual
Meeting, Baltimore, MD, June 2015 (Oral Presentation)
• Yen TC, Ho TY, Chung YH. Defining the Priority of 18F-FDG PET for Curative Intent Concurrent
Chemoradiotherapy in Small Cell Lung Cancer, WMIC, Honolulu, HI, Aug 2015 (Poster)
77
